Bluewillow Biologicsincis A Clinical Stage Biopharmaceutical Company Located In Ann Arbormichiganfounded In 1999The Company Focuses On Developing Innovative Intranasal Vaccines And Anti Infective Productsprimarily Targeting Infectious Diseases And Allergy Immunotherapy The Company Utilizes Its Patented Nanovaxaplatformwhich Creates Oil In Water Nanoemulsions For Intranasal Vaccines And Topical Antiseptic Applicationsthis Technology Is Designed To Stimulate Both Mucosal And Systemic Immune Responsesbluewillow S Vaccine Pipeline Includes Candidates For Significant Diseases Such As H5N1Influenzatuberculosiscovid 19Rsvand Herpes Simplex Virusaiming To Provide Comprehensive Protection Against These Illnessesbluewillow Biologics Has Successfully Raised $97 32 Million In Funding And Is Actively Engaged In The Development Of Its Productswith Several Patents Filed Related To Its Nanotechnology Platform
